PMID- 28786243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1862-1783 (Electronic)
IS  - 1673-1581 (Print)
IS  - 1673-1581 (Linking)
VI  - 18
IP  - 8
DP  - 2017 Aug.
TI  - Interleukin-18, matrix metalloproteinase-22 and -29 are independent risk factors 
      of human coronary heart disease.
PG  - 685-695
LID - 10.1631/jzus.B1700073 [doi]
AB  - BACKGROUND: Coronary heart disease (CHD) is characterized by arterial wall 
      inflammation and matrix degradation. Matrix metalloproteinase (MMP)-22 and -29 
      and pro-inflammatory cytokine interleukin-18 (IL18) are present in human hearts. 
      IL18 may regulate MMP-22 and -29 expression, which may correlate with CHD 
      progression. METHODS AND RESULTS: Immunoblot analysis showed that IL18 induced 
      MMP-22 expression in human aortic smooth muscle cells. The Mann Whitney test from 
      a prospective study of 194 CHD patients and 68 non-CHD controls demonstrated 
      higher plasma levels of IL18, MMP-22 and -29 in CHD patients than in the 
      controls. A logistic regression test suggested that plasma IL18 (odds ratio 
      (OR)=1.131, P=0.007), MMP-22 (OR=1.213, P=0.040), and MMP-29 (OR=1.198, P=0.033) 
      were independent risk factors of CHD. Pearson's correlation test showed that IL18 
      (coefficient (r)=0.214, P=0.045; r=0.246, P=0.031) and MMP-22 (r=0.273, P=0.006; 
      r=0.286, P=0.012) were associated with the Gensini score before and after 
      adjusting for potential confounding factors. The multivariate Pearson's 
      correlation test showed that plasma MMP-22 levels correlated positively with 
      high-sensitive-C-reactive protein (hs-CRP) (r=0.167, P=0.023), and MMP-29 levels 
      correlated negatively with triglyceride (r=-0.169, P=0.018). Spearman's 
      correlation test indicated that plasma IL18 levels associated positively with 
      plasma MMP-22 (r=0.845, P<0.001) and MMP-29 (r=0.548, P<0.001). CONCLUSIONS: Our 
      observations suggest that IL18, MMP-22 and -29 serve as biomarkers and 
      independent risk factors of CHD. Increased systemic IL18 in CHD patients may 
      contribute to elevated plasma MMP-22 and -29 levels in these patients.
FAU - Jin, Dong-Yi
AU  - Jin DY
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Liu, Cong-Lin
AU  - Liu CL
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA 02115, USA.
FAU - Tang, Jun-Nan
AU  - Tang JN
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
AD  - Department of Molecular Biomedical Sciences and Center for Comparative Medicine 
      and Translational Research, College of Veterinary Medicine, North Carolina State 
      University, Raleigh, NC 27695, USA.
FAU - Zhu, Zhao-Zhong
AU  - Zhu ZZ
AD  - Department of Environmental Health, Harvard T.H. Chan School of Public Health, 
      Boston, MA 02115, USA.
FAU - Xuan, Xue-Xi
AU  - Xuan XX
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhu, Xiao-Dan
AU  - Zhu XD
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Wang, Yun-Zhe
AU  - Wang YZ
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Zhang, Tian-Xia
AU  - Zhang TX
AD  - Department of Biology, Pennsylvania State University, University Park, PA 16802, 
      USA.
FAU - Shen, De-Liang
AU  - Shen DL
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Wang, Xiao-Fang
AU  - Wang XF
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
FAU - Shi, Guo-Ping
AU  - Shi GP
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
AD  - Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 
      Boston, MA 02115, USA.
FAU - Zhang, Jin-Ying
AU  - Zhang JY
AD  - Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou 450052, China.
LA  - eng
GR  - R01 HL060942/HL/NHLBI NIH HHS/United States
GR  - R01 HL123568/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PL  - China
TA  - J Zhejiang Univ Sci B
JT  - Journal of Zhejiang University. Science. B
JID - 101236535
PMC - PMC5565516
OTO - NOTNLM
OT  - Interleukin-18; Matrix metalloproteinase (MMP)-22; MMP-29; Coronary heart 
      disease; Risk factor
COIS- Compliance with ethics guidelines: Dong-Yi JIN, Cong-Lin LIU, Jun-Nan TANG, 
      Zhao-Zhong ZHU, Xue-Xi XUAN, Xiao-Dan ZHU, Yun-Zhe WANG, Tian-Xia ZHANG, De-Liang 
      SHEN, Xiao-Fang WANG, Guo-Ping SHI, and Jin-Ying ZHANG declare that they have no 
      conflict of interest. All procedures followed were in accordance with the ethical 
      standards of the responsible committee on human experimentation (institutional 
      and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). 
      Informed consent was obtained from all patients for being included in the study.
EDAT- 2017/08/16 06:00
MHDA- 2017/08/16 06:01
PMCR- 2017/08/01
CRDT- 2017/08/09 06:00
PHST- 2017/08/09 06:00 [entrez]
PHST- 2017/08/16 06:00 [pubmed]
PHST- 2017/08/16 06:01 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - 10.1631/jzus.B1700073 [doi]
PST - ppublish
SO  - J Zhejiang Univ Sci B. 2017 Aug.;18(8):685-695. doi: 10.1631/jzus.B1700073.